Shares of NervGen Pharma (NASDAQ:NGEN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $14.00.
Several brokerages have issued reports on NGEN. Wall Street Zen raised NervGen Pharma from a “sell” rating to a “hold” rating in a report on Monday, July 20th. HC Wainwright upgraded shares of NervGen Pharma to a “strong-buy” rating in a report on Tuesday, April 28th. Leerink Partners initiated coverage on shares of NervGen Pharma in a research report on Monday, July 13th. They issued an “outperform” rating and a $10.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of NervGen Pharma in a research note on Tuesday, July 21st. Finally, Zacks Research raised shares of NervGen Pharma to a “hold” rating in a report on Wednesday, April 29th.
Get Our Latest Report on NervGen Pharma
NervGen Pharma Stock Up 0.6%
NervGen Pharma (NASDAQ:NGEN – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02).
NervGen Pharma Company Profile
NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.
The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.
See Also
- Five stocks we like better than NervGen Pharma
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for NervGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NervGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
